Table 3.
Association between the three-gene signature and clinical pathological parameters in ESCC in cohort 1
| Three-gene signature status |
|||
|---|---|---|---|
| Clinical parameter | Low-risk signature | High-risk signature | r/p |
| Age (yr) | |||
| ≤54 | 43 | 24 | 0.094/0.315 |
| >54 | 45 | 37 | |
| Gender | |||
| Male | 64 | 48 | −0.068/0.446 |
| Female | 24 | 13 | |
| Tumor size (cm) | |||
| ≤3 | 23 | 16 | 0.005/0.969 |
| 3–5 | 47 | 32 | |
| >5 | 18 | 13 | |
| Differentiation | |||
| G1 | 18 | 11 | −0.015/0.874 |
| G2 | 56 | 43 | |
| G3 | 14 | 7 | |
| Invasive depth | |||
| T1 + T2 | 10 | 12 | −0.115/0.240 |
| T3 + T4 | 78 | 49 | |
| Lymph node metastasis | |||
| N0 | 58 | 29 | 0.183/0.029 |
| N1 + N2 + N3 | 30 | 32 | |
| TNM classification | |||
| I (IA + IB) | 3 | 1 | 0.193/0.015 |
| II (IIA + IIB) | 55 | 27 | |
| III (IIIA + IIIB + IIIC) | 26 | 28 | |
| IV | 4 | 5 | |
Statistical analysis: the Kendall's tall-b test.